Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Up 91.6% in August

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 56,865 shares, a growth of 91.6% from the August 15th total of 29,679 shares. Based on an average daily trading volume, of 4,765,370 shares, the short-interest ratio is presently 0.0 days. Currently, 10.1% of the company’s stock are sold short.

Jupiter Neurosciences Price Performance

NASDAQ:JUNS traded up $0.12 during trading hours on Thursday, hitting $3.05. 10,927 shares of the company were exchanged, compared to its average volume of 378,634. Jupiter Neurosciences has a 52-week low of $2.88 and a 52-week high of $137.96. The stock has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.16 and a beta of 1.81. The company’s 50 day moving average price is $6.86 and its 200-day moving average price is $18.47.

Jupiter Neurosciences (NASDAQ:JUNS) last posted its quarterly earnings data on Friday, August 14th. The company reported ($5.06) EPS for the quarter, missing the consensus estimate of ($3.75) by ($1.31). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

A number of large investors have recently bought and sold shares of JUNS. Vestor Capital LLC raised its position in Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after buying an additional 970,314 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Jupiter Neurosciences in the fourth quarter worth $135,000. Finally, Allen Capital Group LLC acquired a new stake in shares of Jupiter Neurosciences in the fourth quarter worth $31,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.